The first ICIs approved by the FDA were Ipilimumab, a human monoclonal anti-CTLA-4 antibody, and Pembrolizumab and Nivolumab targeting the PD-1/PD-L1 interaction, all initially used in the treatment of melanoma [10,11]. The gene discussed is PDCD1; the disease is melanoma.